



An die interessierte Partei / To whom it may concern

Dr. Stefan Dreiheller
Quality Unit / Regulatory Affairs

Date of issue: 20.09.2018
Page 1/1
Doc.-No. EIP-1012
Revision 6

REACH

MEGGLE products:

- Lactose Monohydrate Ph. Eur. / USP-NF / JP: CapsuLac[®] 60, FlowLac[®] 90, FlowLac[®] 100, GranuLac[®] 70, GranuLac[®] 140, GranuLac[®] 200, GranuLac[®] 230, PrismaLac[®] 40, SacheLac[®] 80, SorboLac[®] 400, SpheroLac[®] 100, Tablettose[®] 70, Tablettose[®] 80, Tablettose[®] 100
- Lactose Monohydrate USP-NF / Ph. Eur. / JP: InhaLac[®] 70, InhaLac[®] 120, InhaLac[®] 160, InhaLac[®] 230, InhaLac[®] 250, InhaLac[®] 251, InhaLac[®] 400, InhaLac[®] 500, Lactose monohydrate Low Endotoxin
- Anhydrous Lactose USP-NF / Ph. Eur. / JP: DuraLac[®] H

The intended use of the above mentioned products is relevant regarding registration under REACH. According to Regulation (EC) No. 1907/2006, Art. 2 No. 5 a) and b), the provisions of Titles II (registration), V (downstream users), VI (evaluation) and VII (authorization) do not apply to the extent that a substance is used in medicinal products for human or veterinary use and to the extent that a substance is used in food or feedingstuffs.

Furthermore, Lactose is included to Annex IV of Regulation (EC) No 1907/2006. According to Regulation (EC) No. 1907/2006 Art. 2 No. 7, the provisions of Titles II (registration), V (downstream users), VI (evaluation) do not apply to substances listed in Annex IV as sufficient information is known about these substances that they are considered to cause minimum risk because of their intrinsic properties.

Freundliche Grüße / Best regards


Dr. Stefan Dreiheller